Comparison of the Efficacy of the Fixed-Combination Timolol/Dorzolamide Versus Concomitant Administration of Timolol and Dorzolamide
Authors:
- Jason BacharachJBJason Bacharach
- Maria F. DelgadoMDMaria F. Delgado
- Andrew G. IwachAIAndrew G. Iwach
- 1 April 2003
- journal article
- research article
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 19 (2) , 93-96
Abstract
The purpose of this study was to compare the efficacy of the fixed-combination solution of timolol 0.5%/dorzolamide 2% with the concomitant administration of its components, timolol 0.5% twice a day and dorzolamide 2% twice a day. Ninety-eight patients adequately controlled with a concomitant regimen of timolol and dorzolamide were switched to the fixed-combination regimen of the same components. Intraocular pressures at baseline and 4 weeks after the change in regimen were recorded. The mean baseline intraocular pressure (IOP) was 16.0 ± 5.6 mmHg. Four weeks after the change in medication to the fixed-combination regimen, the mean IOP was 14.5 ± 5.6 mmHg. The mean IOP change from baseline was -1.5 ± 3.9 mmHg. The difference between the two treatment modalities was found to be statistically significant (p-value < 0.001). Eighty-one (83%) patients were considered successfully switched after 4 weeks of fixed-combination therapy, and seventeen eyes (17%) were deemed unsuccessful because a rise in IOP was detected. In conclusion, the fixed combination of timolol 0.5%/dorzolamide 2% twice a day provided equivalent or better intraocular pressure reduction in most patients who were successfully controlled on concomitant administration of its components, timolol and dorzolamide.Keywords
This publication has 6 references indexed in Scilit:
- A comparison of dorzolamide–timolol combination versus the concomitant drugsAmerican Journal of Ophthalmology, 2000
- Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence studyBritish Journal of Ophthalmology, 1998
- The efficacy and safety of the Dorzolamide—timolol combination versus the concomitant administration of its components11Ms. Strohmaier and Drs. Snyder and Adamsons are employees of Merck & Co., Inc, the manufacturer of the dorzolamide-timolol combination. Dr. DuBiner has no proprietary interest in the dorzolamide-timolol combination or Merck.Ophthalmology, 1998
- A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide 11Ms. Clineschmidt, Dr. Adamsons, Dr. Snyder, and Dr. Reines are employees of Merck & Co., Inc., the manufacturer of the dorzolamide-timolol combination. The other authors have no proprietary interest in the dorzolamide-timolol combination or in Merck.Ophthalmology, 1998
- A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide11Ms. Boyle, Dr. Ghosh, and Dr. Adamsons were employees of Merck & Co., Inc, the manufacturer of timolol and dorzolamide, at the time this study was conducted. COSOPT and TRUSOPT are trademark products of Merck & Co., Inc, Whitehouse Station, New Jersey. The other authors have no proprietary interest in timolol, dorzolamide, or Merck.Ophthalmology, 1998
- Drop Size and Initial Dosing Frequency Problems of Topically Applied Ophthalmic DrugsJournal of Pharmaceutical Sciences, 1974